Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?

AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.

Apr 17, 2024 - 00:00
AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Novartis’s XXB...

Next Article

Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Humana projects a tough road for Medicare Advantage, sinking its stock

STAT+: Humana projects a tough road for Medicare Advant...

Jan 26, 2024

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Era of ADCs: Pharma companies innovate to stand out in ...

Aug 13, 2024

STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more

STAT+: Pharmalittle: We’re reading about weight loss dr...

Feb 21, 2024